Cardiovascular Diabetology

(ISSN: 1475-2840)

This journal no longer participates in Medscape Publishers' Circle Program. No new articles will be republished.

Subscribe Submit

Articles Available on Medscape

 
 

Cardiovascular Diabetology's Latest Table of Contents

2017 - 16 (1)

  • Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. 
  • Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. 
  • Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: The Rural Chinese Cohort Study. 
  • Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. 
  • Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. 
  • DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes. 
  • The renal tubular damage marker urinary N-acetyl-β-D-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes. 
  • A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. 
  • The association between diabetes and dermal microvascular dysfunction non-invasively assessed by laser Doppler with local thermal hyperemia: a systematic review with meta-analysis. 
  • Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. 
 
 
Member of Medscape Publishers’ Circle®

Mission Statement: Cardiovascular Diabetology considers manuscripts on all aspects of the diabetes/cardiovascular interrelationship and the dysmetabolic syndrome; this includes genetic, experimental, clinical, pharmacological, epidemiological, molecular biology and laboratory research.

Member of Medscape Publishers’ Circle®